

PROGRAM

EPIGENomics and Health Care Policy: Challenges and Opportunities

December 1-3, 2014

IEO, via Adamello 16, Milan, Italy

December 1, 2014

13:00-14:00 Registration of participants

14:00-14:40 Welcome to IEO and opening remarks

Pier Giuseppe Pelicci (*Scientific Co-Director, European Institute of Oncology, Milan*)

Giuseppe Testa (*European Institute of Oncology & European School of Molecular Medicine, Milan, EPIGEN PI*)

SESSION I

Framing the issues: EPIGEN, the global context of epigenomics and European health care

14:40-15:40 Introduction to the EPIGEN, BLUEPRINT, EPIGENESYS and DEEP Consortia

Giuseppe Macino (*Sapienza University of Rome, EPIGEN Coordinator*)

Henk Stunnenberg (*University of Nijmegen, BLUEPRINT Coordinator*)

Genevieve Almouzni (*Institut Curie, Paris, EPIGENESYS Coordinator*)

Jörn Walter (*Saarland University, Saarbrücken, DEEP Coordinator*)

15:40-16:00 The perspective of the European Commission on Epigenomics and Public Health Policy

TBD

16:00-16:20 Coffee break

SESSION II

High throughput epigenomics: Basic insights and medical applications

16:20-17:10 What is epigenomics?

Gioacchino Natoli (*European Institute of Oncology, Milan*)

Bruno Amati (*Italian Institute of Technology, Milan*)

17:10-18:00 The impact of epigenomics on human health

Davide Gabellini (*Dulbecco Telethon Institute c/o San Raffaele Scientific Institute, Milan, EPIGEN PI*)

Massimiliano Pagani (*National Institute for Molecular Genetics, Milan, EPIGEN PI*)

18:00-18:30 Discussion

December 2, 2014

SESSION III

High throughput epigenomics: Industrial perspectives

9:00-10:30 Epigenomics, industry and drug development

Saverio Minucci (*European Institute of Oncology, Milan; EPIGEN PI*)

Udo Oppermann (*University of Oxford, Oxford*)

Alex Gutteridge (*Neusentis, a Pfizer research unit*)

10:30-11:00 Discussion

11:00-11:30 Coffee break

SESSION IV

Focus groups on disease areas

11:30-13:00 Participants' focus groups on three disease areas (Cancer/Neurodegenerative diseases/Cardiovascular and metabolic diseases)

Supervised and moderated by EPIGEN PIs

13:00-14:30 Lunch

SESSION V

Ethical and legal implications of epigenomics in health care delivery

14:30-15:30 What are the ethical and social implications of epigenomics?

Ruth Chadwick (*Cardiff School of English, Communication and Philosophy, Cardiff*)

Yann Joly (*McGill University, Montreal; IHEC Working Group on Ethics*)

15:30-16:00 Discussion

16:00-16:30 Coffee break

16:30-18:00 Paving the way for epigenomics into healthcare practice: the European regulatory landscape for biotechnologies

Nils Hoppe (*Centre for Ethics and Law in the Life Sciences, Hannover*)

Barbara Prainsack (*King's College, London*)

Maurizio Meloni (*Princeton and University of Sheffield*)

18:00-18:30 Discussion

Social event

December 3, 2014

SESSION VI

Social epigenetics and epidemiology

9:00-10:30 Social epigenetics and epidemiology

Hannah Landecker (*Institute for Society and Genetics, Los Angeles*)

Karin Michels (*Harvard School of Public Health, Boston*)

Silvia Stringhini (*Lausanne University Hospital, Lausanne*)

10:30-11:00 Discussion

11:00-11:30 Coffee break

SESSION VII

The EPIGEN contribution

11:30-12:00 Introducing the EPIGEN Whitepaper on Epigenomics in Health Care Policy

Giuseppe Testa (*European Institute of Oncology & European School of Molecular Medicine, Milan; EPIGEN PI*)

12:00-13:00 Round table: Evaluating the EPIGEN Policy Framework

Round table and panel discussion with selected guests and EPIGEN PIs, chaired by **Luca Chiapperino** and **Maria Damjanovicova** (*European School of Molecular Medicine, Milan*)

13:00-13:30 Concluding remarks and farewell